These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 15042681)

  • 1. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
    Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
    Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
    J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
    Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
    Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
    Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
    Kim YT; Lee SH; Sung SW; Kim JH
    Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
    Kim JS; Han J; Shim YM; Park J; Kim DH
    Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
    Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
    Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
    Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
    Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
    Brabender J; Usadel H; Metzger R; Schneider PM; Park J; Salonga D; Tsao-Wei DD; Groshen S; Lord RV; Takebe N; Schneider S; Hölscher AH; Danenberg KD; Danenberg PV
    Clin Cancer Res; 2003 Jan; 9(1):223-7. PubMed ID: 12538473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
    Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
    Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation markers and early recurrence in stage I lung cancer.
    Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
    N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung.
    Kim YT; Park SJ; Lee SH; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1378. PubMed ID: 16256792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer.
    Kim H; Kwon YM; Kim JS; Han J; Shim YM; Park J; Kim DH
    Cancer; 2006 Sep; 107(5):1042-9. PubMed ID: 16888795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
    Kikuchi S; Yamada D; Fukami T; Maruyama T; Ito A; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Cancer; 2006 Apr; 106(8):1751-8. PubMed ID: 16534787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.